• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Expert Ratings For Warby Parker

    7/10/24 3:00:51 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email

    In the last three months, 4 analysts have published ratings on Warby Parker (NYSE:WRBY), offering a diverse range of perspectives from bullish to bearish.

    The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 1 3 0 0
    Last 30D 0 0 1 0 0
    1M Ago 0 0 0 0 0
    2M Ago 0 0 0 0 0
    3M Ago 0 1 2 0 0

    Analysts have set 12-month price targets for Warby Parker, revealing an average target of $16.0, a high estimate of $19.00, and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 6.67% increase from the previous average price target of $15.00.

    price target chart

    Analyzing Analyst Ratings: A Detailed Breakdown

    The analysis of recent analyst actions sheds light on the perception of Warby Parker by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Anthony Chukumba Loop Capital Raises Hold $16.00 $15.00
    Mark Carden UBS Raises Neutral $15.00 $13.00
    Kimberly Greenberger Morgan Stanley Raises Equal-Weight $14.00 $13.00
    Dana Telsey Telsey Advisory Group Maintains Outperform $19.00 $19.00

    Key Insights:

    • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Warby Parker. This information provides a snapshot of how analysts perceive the current state of the company.
    • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Warby Parker compared to the broader market.
    • Price Targets: Analysts predict movements in price targets, offering estimates for Warby Parker's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

    Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Warby Parker's market standing. Stay informed and make data-driven decisions with our Ratings Table.

    Stay up to date on Warby Parker analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    Unveiling the Story Behind Warby Parker

    Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

    Financial Insights: Warby Parker

    Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

    Revenue Growth: Warby Parker displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 16.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.

    Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.34%, the company may need to address challenges in effective cost control.

    Return on Equity (ROE): Warby Parker's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.87%, the company may face hurdles in achieving optimal financial performance.

    Return on Assets (ROA): Warby Parker's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.46%, the company may encounter challenges in delivering satisfactory returns from its assets.

    Debt Management: Warby Parker's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.57.

    Analyst Ratings: Simplified

    Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

    Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $WRBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    12/10/2025$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    11/7/2025$28.00 → $24.00Outperform
    Telsey Advisory Group
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    More analyst ratings

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

    Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-

    11/26/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

    SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

    1/23/26 11:08:18 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    1/13/26 4:21:45 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    1/7/26 4:24:30 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Blumenthal Neil Harris sold $19,793 worth of shares (660 units at $29.99) and converted options into 660 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:36:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham converted options into 80,094 shares and sold $2,359,569 worth of shares (80,094 units at $29.46) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:35:24 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham converted options into 94,906 shares and sold $2,610,816 worth of shares (94,906 units at $27.51) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/9/26 8:48:36 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warby Parker upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Warby Parker from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    12/10/25 9:45:30 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $24.00 from $28.00 previously

    11/7/25 7:48:31 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Second Quarter 2025 Results

    Net revenue increased 14% year over year to $214 million; Raises outlook Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. "It has been a busy and exciting year marked by major milestones. We celebrated opening our 300th store and distributing 20 million pairs of glasses to people in need around the world. Looking ahead, our partnership with Google to develop intelligent eyewear is a testament to Warby Parker's commitment to innovation as we shape the future of how people

    8/7/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care